Furthermore, the combination of IL-2 immunocytokines with checkpoint inhibitors, chemotherapy, radiotherapy, and anti-angiogenic agents has elicited robust anti-tumor responses in both preclinical and early clinical trials, effectively improving tumor clearance while minimizing toxicity. Here, IL2 is linked to neoplasm.